Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| C1723 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Hereditary Hemorrhagic Telangiectasia NGS Panel | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of hereditary hemorrhagic telangiectasia. Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder characterized by telangiectases and arteriovenous malformations (AVMs) of the skin, mucosa and viscera. Common findings include frequent nose bleeds, gastrointestinal bleeding and telangiectases on the face, lips, tongue, fingers, and chest. AVMs can also occur within the lungs, liver, and brain, and are a significant cause of morbidity. Recommended for individuals with a personal and/or family history of hereditary hemorrhagic telangiectasia to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Alternate Names | ||||||||||||||||||||||||||||||
| HHT | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder characterized by telangiectases and arteriovenous malformations (AVMs) of the skin, mucosa and viscera. Epistaxis is the most frequent presenting finding. Gastrointestinal bleeding and telangiectases on the face, lips, tongue, fingers, and chest are other common clinical features. AVMs within the lungs, liver, and brain are a significant cause of morbidity. Pulmonary AVMs lead to morbidity via direct hemorrhage, heart failure, or shunting of emboli with subsequent brain abscess formation or stroke. AVMs involving the liver can result in hyperdynamic circulation and cause high output heart failure. Additionally, intrahepatic arteriovenous shunts may lead to cirrhosis and resultant bleeding esophageal varices. Cerebrovascular malformations causing intracranial hemorrhage also occur. Other organs known to be affected by telangiectasia or AVMs include the bladder, eyes and kidneys.
|
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| ACVRL1, ENG, GDF2, RASA1, SMAD4 | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 187300, 600376, 615506 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Cardiovascular Disorders, Hair and Nail disorders, Skin, Tooth | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.